Skip to main content
OpenTrials
Completed

NCT Number: NCT01071642

The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Pressure

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Talya Wolak

Bear Sheva, 8410, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Age>18 years
  • 2. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file)
  • 3. Subjects planned to undergo non-emergent coronary angiography.
  • 4. Signed informed consent

Exclusion criteria

  • 1. eGFR<30 ml/min at baseline
  • 2. Chronic utilization of NSAIDS and Cox-2 selective inhibitors
  • 3. Chronic treatment with mineralocorticosteroid receptor blocker
  • 4. Systolic blood pressure<90 mmHg
  • 5. Planned staged (repeated) procedure within 48 hours
  • 6. Administration of contrast within 14 days prior to the enrollment
  • 7. contraindication to stop ACE-I or ARB'S

Treatment and study plan

stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure

Drug

ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

ACE/ARB stopped 24 hours before procedure and start immediately after

Drug

ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure

Primary outcomes

  1. Change in eGFR from baseline to 48 hours following the exposure to the contrast.

    Time frame: 48 hours after exposure to the contrast

Secondary outcomes

  1. 1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization,

    Time frame: 48-72 hours after exposure to contrast

Sponsors and collaborators

Lead sponsor

Soroka University Medical Center

Other

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Feb 19, 2010
Registry last updated
Jun 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.